Non-Diabetic Neuropathic Ulcers: Billing and ICD-10 Guide

Neuropathic foot ulcers in non-diabetic patients are one of the most underrecognized billing problems in wound care. The workflows, documentation templates, and LCD criteria most practices build assume diabetic etiology — leaving non-diabetic neuropathic ulcers in a gray zone that generates denials, undercoding, and missed revenue. When a patient's neuropathy comes from chemotherapy, alcoholism, Charcot-Marie-Tooth disease, or idiopathic causes, the ICD-10 coding changes, the LCD pathway shifts, and the documentation requirements demand a different approach. This guide covers each of those differences directly.

Common Causes of Non-Diabetic Neuropathic Ulcers

Non-diabetic neuropathy is more prevalent than most wound care practices recognize. Any of the following conditions can produce peripheral neuropathy severe enough to cause pressure-related foot ulcers:

Chemotherapy-induced peripheral neuropathy (CIPN) is the leading cause of non-diabetic neuropathy in oncology populations. Platinum agents (cisplatin, carboplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), and vinca alkaloids produce dose-dependent sensory neuropathy. Patients completing or continuing cancer treatment who lose protective sensation are at high risk for plantar ulceration at pressure points.

Alcohol-related neuropathy presents clinically similar to diabetic neuropathy but affects a population with frequent social barriers, wound care compliance challenges, and overlapping nutritional deficiencies — thiamine and B12 deficiencies that further impair healing.

Hereditary neuropathies — most commonly Charcot-Marie-Tooth (CMT) disease — affect both foot structure and protective sensation. CMT patients frequently have cavus foot deformities and hammer toes that create abnormal plantar pressure distribution, leading to ulceration at predictable sites.

Idiopathic peripheral neuropathy accounts for a substantial portion of cases in Medicare-age patients. When no clear etiology emerges after workup, the condition is coded as idiopathic but the ulcer mechanism and documentation needs are identical to other neuropathic causes.

HIV-associated neuropathy and neuropathy secondary to autoimmune conditions — including lupus, Sjogren's syndrome, and systemic vasculitis — round out the major non-diabetic categories encountered in mobile and SNF wound care settings.

ICD-10 Coding for Non-Diabetic Neuropathic Ulcers

The correct ICD-10 code set for a non-diabetic neuropathic ulcer depends on the underlying cause of the neuropathy, not just the wound's location or depth. This is where practices most commonly generate avoidable denials.

For a plantar or lower extremity ulcer in a non-diabetic patient, the wound code is drawn from the L97 category (non-pressure chronic ulcer of lower limb), with fifth and sixth characters specifying anatomic site and tissue depth. The L97 codes do not inherently indicate etiology — you must pair them with the corresponding neuropathy diagnosis code to establish medical necessity under the applicable LCD.

Correct etiology-first sequencing:

CIPN ulcer: G62.0 (drug-induced polyneuropathy) + adverse effect T-code + L97.x
Alcoholic neuropathy ulcer: G62.1 (alcoholic polyneuropathy) + L97.x
CMT disease ulcer: G60.0 (hereditary motor and sensory neuropathy) + L97.x
Idiopathic neuropathy ulcer: G60.9 (hereditary and idiopathic neuropathy, unspecified) + L97.x

The etiology code is sequenced first. The wound code follows. If the neuropathy diagnosis is absent from the wound care note, the claim lacks the causal chain most LCDs require to establish coverage.

For a comprehensive ICD-10 framework that covers all wound types beyond neuropathic ulcers, see the wound care ICD-10 complete coding guide.

Adverse Effect vs. Manifestation Coding for Drug-Induced Neuropathy

CIPN coding requires one additional step that frequently traps coders. Neuropathy from a correctly prescribed chemotherapy agent is an adverse effect — not a poisoning. Adverse effect coding requires two code entries:

G62.0 — drug-induced polyneuropathy (the condition/manifestation)
The appropriate T code from the T36–T50 range, seventh character "A" (initial encounter), "D" (subsequent encounter), or "S" (sequela), identifying the specific causative agent

For oxaliplatin neuropathy, the pairing would be G62.0 + T45.1X5D (adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter). For taxane neuropathy, the same T45.1X5_ structure applies.

If the T code is missing, the adverse effect claim is technically incomplete. Some MACs will still pay; others deny for missing causal documentation. Build the T code into your template for any CIPN patient so the coder doesn't have to reconstruct the agent from the note after the visit.

Medicare LCD Requirements for Non-Diabetic Neuropathic Ulcers

Non-diabetic neuropathic ulcers can qualify for advanced wound care — including skin substitutes — under the major wound care LCDs (L33831, L37166, L38720), because those LCDs cover chronic non-healing lower extremity ulcers broadly. The documentation burden, however, is higher for non-diabetic causes because reviewers are less familiar with the etiology pathway.

Three documentation elements are non-negotiable:

1. Neuropathic etiology documented clinically. The note must establish the presence of peripheral neuropathy with loss of protective sensation, tied to a specific etiology. Monofilament testing results (10g monofilament), vibration perception threshold, or reference to prior neurological workup all serve this purpose. "History of peripheral neuropathy" without etiology or test results provides weak support during a review.

2. Conservative treatment failure threshold met. The same 30-day standard wound care failure threshold that applies to diabetic foot ulcers applies here. Documentation must show debridement, offloading, moisture management, and infection control over a minimum 30-day period with serial wound measurements demonstrating inadequate progression (typically defined as less than 40% area reduction in four weeks for skin substitute eligibility under most LCDs).

3. Offloading documented. For plantar neuropathic ulcers, total contact casting or an equivalent offloading modality is expected documentation in an LCD-compliant note. Absence of offloading documentation in a plantar neuropathic ulcer draws scrutiny regardless of wound etiology. If the patient is unable to tolerate TCC, document why and what alternative offloading was prescribed.

The LCD compliance architecture that protects diabetic ulcer claims applies equally to non-diabetic neuropathic ulcers. Review the specific documentation thresholds for your MAC jurisdiction using the wound care LCD compliance guide.

Billing Skin Substitutes and Debridement for Non-Diabetic Neuropathic Ulcers

Skin substitutes are billable for qualifying non-diabetic neuropathic ulcers using the same Q-codes and CPT codes that apply to diabetic foot ulcers, provided the LCD criteria above are met. The 2026 CMS flat rate of $127.14/sq cm applies to Tier 2 skin substitute products regardless of the underlying ulcer etiology.

Debridement coding follows the standard tissue-depth hierarchy for any wound:

CPT 97597/97598 — selective debridement (active wound management), billed per 20 sq cm wound surface area
CPT 11042–11044 — excisional debridement when subcutaneous tissue, muscle/fascia, or bone is debrided

The full debridement code hierarchy and documentation requirements for each level are covered in the wound care CPT codes 2026 reference.

Total contact casting for non-diabetic neuropathic ulcers is billed under CPT 29445 using the same documentation framework as for diabetic offloading. The underlying neuropathy diagnosis code — not a diabetes diagnosis — is the medical necessity anchor. Confirm your MAC's specific documentation requirements for non-diabetic TCC claims, as some LCD companion articles include explicit language about diabetic ulcers for the casting benefit.

One missed revenue opportunity that appears regularly: if the patient also receives an E/M service on the same day as wound care, append Modifier 25 to the E/M code to bill both services when the evaluation represents a separately identifiable service. Patients with active oncology care, autoimmune conditions, or progressive hereditary neuropathy often require more complex medical decision-making at each wound care visit — capture that complexity with appropriate E/M leveling and document the separate problem addressed.

Key Takeaways

Non-diabetic neuropathic ulcers from CIPN, alcoholic neuropathy, hereditary neuropathy, or idiopathic causes can qualify for skin substitutes and advanced wound care under the same MAC LCDs that cover diabetic foot ulcers.
ICD-10 coding requires the neuropathy etiology code (G60.x or G62.x) sequenced before the wound code (L97.x); for CIPN, an adverse effect T-code identifying the chemotherapy agent is also required.
Clinical documentation must explicitly establish neuropathic etiology with objective findings — monofilament or vibration test results, or documented neurological diagnosis — not merely note the absence of diabetes.
The 30-day conservative treatment failure threshold and offloading documentation requirements apply equally to non-diabetic neuropathic ulcers as to any other chronic lower extremity ulcer under current LCD frameworks.
CIPN and autoimmune neuropathy patients often carry active comorbidities that support higher E/M levels on wound care visit dates; document the separately identifiable medical decision-making and bill Modifier 25.